Cure8 news brief
Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing durable treatment options.
Adults with moderately to severely active Crohn’s disease, people who have failed prior biologics, clinicians prescribing IBD biologics, and researchers following IL-23-targeted therapies.
This is a report of longer-term outcomes from an open-label extension following phase 3 studies — not a new randomized trial. The results described are proportions of patients maintaining or achieving clinical and endoscopic remission or response over two years on continued mirikizumab treatment.
The article does not provide detailed safety data, patient-level outcomes, or statistical analyses here. If you use or are considering biologic therapy: these findings are relevant as evidence for durability of effect with mirikizumab, especially for some patients who previously failed other biologics.
Discuss specifics, including benefits and risks, with your treating clinician to understand whether this therapy and the evidence apply to your situation.
This article summarizes company-reported results from an open-label extension presented at a conference; open-label extensions lack a control arm and can be subject to selection or attrition bias. The piece does not include full safety or detailed statistical information. Regulatory review in Europe is ongoing; FDA approval in the US for Crohn’s disease was already mentioned.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...
This gives adults with moderately to severely active Crohn’s disease an additional FDA-approved biologic option that targets the IL-23 pathway. Approval was supported by late-stage trial results showing improvements in...
A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...
